Find and Pitch Jounalists, Get Your Story Covered

Tags: hardware robotics startups funding industrial robotics

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 5 days ago STAT+: Up and down the ladder: The latest comings and goings - about 1 month ago STAT+: Up and down the ladder: The latest comings and goings - about 2 months ago STAT+: Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds - 2 months ago STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 2 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 10 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - about 1 year ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - about 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago
2	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking - 5 days ago The ability to pivot will be ‘key’ as pharma’s tariff threat looms - 9 days ago PharmaVoice’s Crystal Ball: The industry’s AI future - 15 days ago 3 closely watched drugs that failed in the clinic - about 1 month ago Pharma takes aim at a wily foe — the Epstein-Barr virus - 3 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - 3 months ago 2024 PharmaVoice 100s: Trailblazers - 3 months ago What 3 layoff stories reveal about pharma’s troubles - 5 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 5 months ago Is anyone taking the world’s priciest drugs? - 5 months ago What pharma has learned from AI - 6 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 8 months ago Where competition is heating up in pharma - 8 months ago The biggest questions hanging over pharma in 2024 - 12 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - about 1 year ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - about 1 year ago 3 standout digital innovations in pharma this year - about 1 year ago PharmaVoice 100s: Entrepreneurs - about 1 year ago PharmaVoice 100s: Clinical trial gurus - over 1 year ago
3	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Oncology, obesity and more: Where pharma R&D is headed in 2025 - about 1 month ago From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies - 2 months ago M&A is ready to explode, and that’s good news for pharma layoffs - 5 months ago As the GLP-1 market booms, other healthcare companies are cashing in - 7 months ago As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene - 10 months ago
4	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 2 months ago
5	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 2 months ago
6	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 2 months ago
7	Beth Mole Ars Technica Senior Health Reporter @ArsTechnica. microbiologyinfectious diseasespublic health	Big Pharma’s fight against drug price reforms takes weird, desperate turn - 7 months ago
8	Kelly Bilodeau Pharma Voice Mom, wife, freelance writer. writing	Pharma has a misinformation problem — and execs could be on the hook - 12 months ago Pharma takes a gut check of microbiome drugs - about 1 year ago What are pharma’s next blockbusters? - about 1 year ago Oncology drugmakers seek the sweet spot between efficacy and tolerability - about 1 year ago Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline. - about 1 year ago From the rainforest to Wall Street — Jaguar Health’s big play for revitalization - over 1 year ago
9	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	2024 - 12 months ago
10	Nicholas Florko STAT News Reports on US health business. Washington, DC healthcarepolicy	STAT+: Medical marijuana companies are using pharma’s sales tactics with little of the same scrutiny - about 1 year ago STAT+: FDA’s Woodcock, other experts highlight persistent issues plaguing pharma, biotech in the wake of Covid-19 - about 1 year ago

Journalists covering pharma industry